Biolegend, 505807, PE anti-mouse IFN-γ Antibody, 25μg

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.
25μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: E. coli-expressed, recombinant mouse IFN-γ
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: ICFC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812). Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations. Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry. Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.
Application References(PubMed link indicates BioLegend citation): Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut) Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut) Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut) Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT) Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC) Ferrick D, et al. 1995. Nature 373:255. (FC) Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut) DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Montfort M, et al.2004. J. Immunol. 173:4084. PubMed Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC) Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations: Wang H, et al. 2013. J Immunol. 191:6010. PubMed Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed Chen Y, et al. 2020. Virol Sin. . PubMed Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed Yu X, et al. 2020. Nat Commun. 11:1110. PubMed Chen R, et al. 2022. J Mol Cell Biol. 14:. PubMed Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed Li D, et al. 2023. Ann Med. 55:2189295. PubMed Zuo B, et al. 2023. Clin Transl Oncol. . PubMed Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed Deng G, et al. 2023. Cancers (Basel). 15:. PubMed Wang Y, et al. 2023. iScience. 26:106630. PubMed Gao Y, et al. 2023. iScience. 26:106729. PubMed Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed Yang QC, et al. 2023. iScience. 26:106916. PubMed Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed Miki H, et al. 2020. J Immunol. 204:1892. PubMed Zhang H, et al. 2022. Eur J Immunol. 52:978. PubMed Jia JJ, et al. 2022. J Leukoc Biol. 112:157. PubMed Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed Tu J, et al. 2022. Cancer Sci. 113:2496. PubMed Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed Kang IH, et al. 2022. iScience. 25:104818. PubMed Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed Xu H, et al. 2022. Aging Dis. 13:1875. PubMed Tan TCJ, et al. 2022. Nat Commun. 13:7796. PubMed Wang Z, et al. 2022. Cell Rep. 41:111890. PubMed Chan L, et al. 2022. Cells. 12: . PubMed Liu H, et al. 2023. Cell Death Differ. :. PubMed Mandour MF, et al. 2023. Front Med (Lausanne). 9:1057252. PubMed Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed Tan L, et al. 2022. Aging Dis. 13:1562. PubMed Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed Lin W, et al. 2020. Theranostics. 10:4871. PubMed Zhou J, et al. 2019. Immunity. 50:403. PubMed Shi L, et al. 2019. Theranostics. 9:4115. PubMed Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed Li X, et al. 2022. Nat Commun. 13:2794. PubMed Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed Dong L, et al. 2021. Cancer Cell. . PubMed Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed Wang X, et al. 2018. Int Immunopharmacol. 56:249. PubMed Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed Kiritsy MC, et al. 2021. Elife. 10:. PubMed Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed Herman JD, et al. 2021. Nat Commun. 12:6853. PubMed Galeano Niño JL, et al. 2020. J Cell Sci. . PubMed Saito S, et al. 2020. Nutrients. 12:. PubMed Koenecke C, et al. 2012. J Immunol. 189:2890. PubMed Michel M, et al. 2012. Proc Natl Acad Sci U S A. 109:17459. PubMed Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed Chen D, et al. 2018. Nat Commun. 9:873. PubMed Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed Sharma S, et al. 2015. J Immunol. 194:5529. PubMed Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed Ning X, et al. 2019. Mol Cell. 74:19. PubMed Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed Dai B, et al. 2022. Theranostics. 12:7603. PubMed Kuttke M, et al. 2022. Front Immunol. 13:695576. PubMed Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed Subbiah J, et al. 2022. NPJ Vaccines. 7:68. PubMed Wang C, et al. 2021. Cell Rep. 37:110021. PubMed Wan Y, et al. 2014. Vaccine. 41:241. PubMed Sandrock I, et al. 2015. PLoS One. 10: 0145010. PubMed Koren N, et al. 2021. Cell Host Microbe. 29(2):197-209.e5. PubMed Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed Probst P, et al. 2017. Cancer Res. 77:3644. PubMed Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed An J, et al. 2022. iScience. 25:103570. PubMed Han JP, et al. 2022. Sci Adv. 8:eabj6901. PubMed Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed Shami A, et al. 2015. Sci Rep. 5: 13904. PubMed Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed Hegde S, et al. 2020. Cancer Cell. 37(3):289-307. PubMed Srey MT, et al. 2020. PLoS Negl Trop Dis. 14:e0008842. PubMed Chen D, et al. 2022. J Neuroinflammation. 19:112. PubMed Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed Canton J, et al. 2021. Nat Immunol. 22:140. PubMed Cho K, Hill A 2008. J Immunol Methods. 330:137. PubMed Condotta S, et al. 2015. J Immunol. 195: 116 - 125. PubMed Satoh M, et al. 2016. Sci Rep. 6:28473. PubMed Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed Hundt M, et al. 2009. J Immunol. 183:1685. PubMed Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed Sartorius R, et al. 2015. EMBO Mol Med. 7: 973 - 988. PubMed Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed Li W, et al. 2019. Nat Commun. 10:3349. PubMed Yan Y, et al. 2018. JCI Insight. 3. PubMed Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed Reese B, et al. 2020. J Immunol. 205:3218. PubMed Ma Y, et al. 2013. J Immunol. 190:5588. PubMed Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed QT N, et al. 2015. Antimicrob Agents Chemother. 59: 6308-6316. PubMed Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed Galeano Niño JL, et al. 2020. J Cell Sci. 133:00:00. PubMed Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed Tian X, et al. 2022. J Cell Mol Med. 26:693. PubMed Yan J, et al. 2020. Cell Rep. 107820:31. PubMed Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed Ren Y, et al. 2015. Sci Rep. 5: 18099. PubMed Kraus Z, et al. 2008. J Immunol. 181:7800. PubMed Lin W, et al. 2019. EBioMedicine. 49:133. PubMed Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed De Ponte Conti B, et al. 2021. Elife. 10:. PubMed Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed Karandikar SH, et al. 2019. JCI Insight. 5. PubMed Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed Montfort M, et al. 2004. J Immunol. 173:4084. PubMed Xu Q, et al. 2021. Theranostics. 11:1937. PubMed Guo S, et al. 2021. Sci Rep. 11:23745. PubMed Wang Y, et al. 2020. Virol Sin. 36:122. PubMed Hirata SI, et al. 2020. Allergy. 75:1939. PubMed Castiglioni P, et al. 2017. PLoS Negl Trop Dis. 10.1371/journal.pntd.0005240. PubMed Kalafati L, et al. 2020. Cell. 183:771. PubMed Roy S, et al. 2019. Front Immunol. 2.404166667. PubMed Yuan X, et al. 2017. Elife. 6:e29540. PubMed Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed Zhang J, et al. 2018. Nature. 553:91. PubMed Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed Miao W, et al. 2020. J Immunol. 1486:204. PubMed Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed Li H, et al. 2021. Front Immunol. 12:739605. PubMed Kiritsy MC, et al. 2021. Elife. 10:. PubMed Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed Lee J, et al. 2007. Nat Immunol. 8:181. PubMed Tian D, et al. 2019. Nat Commun. 10:4246. PubMed Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed Johnson RM, et al. 2021. Front Immunol. 11:614697. PubMed Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed Molgora M, et al. 2020. Cell. 182:886. PubMed Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed Tomaru U et al. 2019. Cell reports. 26(3):639-651 . PubMed Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed Chen L, et al. 2021. Theranostics. 11:6668. PubMed Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed Wang Y, et al. 2021. Front Immunol. 11:601601. PubMed Prakash MD, et al. 2021. PLoS One. 16:e0247492. PubMed Zhang X, et al. 2020. J Cancer. 11:648. PubMed Zhao K, et al. 2021. Biomed Res Int. 7619849:2020. PubMed Charlton J, et al. 2015. PLoS One. 10:119200. PubMed Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed Li H, et al. 2022. iScience. 25:104481. PubMed Schmit T, et al. 2022. Cell Rep. 38:110456. PubMed Zhang X, et al. 2021. Front Pharmacol. 12:706748. PubMed Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed Gaylo A, et al. 2013. Transpl Immunol. 20:163. PubMed Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed Zheng Y, et al. 2022. Transl Res. :. PubMed Nabekura T, et al. 2020. Immunity. 96:52. PubMed Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed Qi S, et al. 2020. Theranostics. 10:1814. PubMed Chen S, et al. 2018. Nat Commun. 9:5298. PubMed Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed Song X, et al. 2022. Transl Oncol. 15:101306. PubMed Yang F, et al. 2021. Nat Commun. 12:3424. PubMed Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID: AB_315401 (BioLegend Cat. No. 505807) AB_315402 (BioLegend Cat. No. 505808)
Structure: Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity: Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources: CD8+ and CD4+ T cells, NK cells
Cell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type: Tregs
Biology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.
Regulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID: 15978
UniProt: View information about IFN-gamma on UniProt.org
Clone: XMG1.2
Regulatory Status: RUO
Other Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype: Rat IgG1, κ
Q: What type of PE do you use in your conjugates?
A: We use R-PE in our conjugates.